Mesoblast MESO
NASDAQ MESO
$12.83 +0.42 (+3.38%)
At close: Oct 21, 2026 · 4:00 PM EDT

Mesoblast (MESO) Accumulated Expenses (2024 - 2026)

Updated

Analysis

Mesoblast (MESO) Accumulated Expenses (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Mesoblast 1.66 Bn 1.23 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7.36 Mn
Dec 31, 2025 11.03 Mn
Jun 30, 2025 10.79 Mn
Jun 30, 2024 10.62 Mn
API Access

Mesoblast Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=MESO&period=max&api_key=YOUR_API_KEY